For gastric cancer, the predominant mechanisms that confer resistance to HER2-targeted therapy have been identified as the loss of HER2 amplification after treatment and the activation of alternative pathways, such as MET and EGFR [5,7,60]. Here, ERBB2 is linked to gastric cancer.